Pediatrics

2

Xilaplus® launched in France by Therabel

Noventure is proud to announce the launch of XILAPLUS® in France by its long-term partner company Therabel, under the brand name Diastil Diarrhée. XILAPLUS® is specifically formulated for the control and reduction of diarrheal events of various etiologies. It acts by forming a film which protects the intestinal mucosa, reducing the frequency and duration of diarrhea episodes and associated symptoms in adults, children, and infants.

Read more

Noventure is delighted to announce the launch of Tasectan® in Russia by its partner company Jadran, under the umbrella brand Adiarin®

Adiarin® is recommended for the protection of gut lining in diarrhea in children and adults. It is the first Noventure product in Russia. Tasectan® in Europe is a class III medical device and complies with the Essential Requirements of Directive 93/42/EEC and subsequent amendments. (CE 0373, Novinthetical Pharma SA). In Russia, Adiarin® has been granted local marketing authorization as class II medical device.

Read more

Xyloglucan, a Plant Polymer with Barrier Protective Properties over the Mucous Membranes: An Overview

Núria Piqué, María del Carmen Gómez-Guillén and María Pilar Montero

Disruption of the epithelial barrier function has been recently associated with a variety of diseases, mainly at intestinal level, but also affecting the respiratory epithelium and other mucosal barriers. Non-pharmacological approaches such as xyloglucan, with demonstrated protective barrier properties, are proposed as new alternatives for the management of a wide range of diseases, for which mucosal disruption and, particularly, tight junction alterations, is a common characteristic.

Read more

Let's meet in..

2021, Mar 01

euroPLX 75 Lisbon

Read more